02:39 PM EST, 03/08/2024 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) plunged 82% amid heavy trading after the company said Friday its phase 3 trial assessing AMX0035 in people with amyotrophic lateral sclerosis failed to meet the primary and secondary endpoints.

More than 54 million shares traded intraday compared with the stock's daily average of about 1.2 million.

BigBear.ai ( BBAI ) reported late Thursday Q4 results that trailed analysts' net loss and sales estimates.

Shares slumped 30%, with intraday trading volume at over 34.1 million versus a daily average of about 7.85 million.

AerSale ( ASLE ) shares fell after the company swung to a loss in Q4 amid lower revenue

Shares dropped 26% as intraday trading volume jumped to more than 2.8 million versus a daily average of about 590,000.

Price: 3.38, Change: -15.59, Percent Change: -82.18